Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989156 · ClinicalTrials.gov registry record · NA
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting
A NA study, sponsored by Philip Morris Products S.A..
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT01989156 is a NA study that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 160 participants.
The verdict
NCT01989156, a NA study, has completed, sponsored by Philip Morris Products S.A..
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
Evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product, for 5 days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy smokers results in a reduction in the levels of biomarkers of exposure (BoExp) to selected harmful and potentially harmful constituents (HPHCs).
Interventions
- OTHER THS 2.2 Menthol (mTHS 2.2)
- OTHER Menthol Conventional Cigarette (mCC)
- OTHER Smoking Abstinence (SA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989156
The ClinicalTrials.gov registry entry for NCT01989156 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Morris Products S.A., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which THS 2.2 Menthol (mTHS 2.2) is the first listed.
NCT01989156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989156 about?
NCT01989156 is a clinical study titled "Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting". Evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product, for 5 days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy smokers results in a reduction in the levels of biomarkers of exposure (BoExp) to selected harmf...
What is the current status of trial NCT01989156?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2013-12. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01989156?
The interventions under investigation include: THS 2.2 Menthol (mTHS 2.2) (OTHER), Menthol Conventional Cigarette (mCC) (OTHER), Smoking Abstinence (SA) (OTHER).
Who is sponsoring clinical trial NCT01989156?
This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.